UCB Pharma withdraws its marketing authorisation application for Lacosamide Pain UCB Pharma

View source ↗

Summary

UCB Pharma has withdrawn its marketing authorization application for Lacosamide Pain in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain
• Pain Management

Drugs mentioned

• Lacosamide Pain (lacosamide)